UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
STERIS plc STERIS Irish FinCo Unlimited Company | Ireland Ireland | 98-1455064 98-1271422 | ||
(Exact name of registrant as specified in its charter) | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
70 Sir John Rogerson’s Quay
Dublin 2 Ireland D02 R296
+353 1 232 2000
(Address of principal executive offices)
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class | Name of each exchange on which | |
2.700% Senior Notes due 2031 3.750% Senior Notes due 2051 | The New York Stock Exchange The New York Stock Exchange |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates:
333-254608
Securities to be registered pursuant to Section 12(g) of the Act:
None.
EXPLANATORY NOTE
On March 23, 2021, STERIS plc, an Irish public limited company (“STERIS”), and certain of its wholly owned subsidiaries, including STERIS Irish FinCo Unlimited Company, an Irish public unlimited company (the “Issuer”), filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-3 (File No. 333-254608) (the “Registration Statement”) relating to, among other securities, certain debt securities of the Issuer that may be guaranteed by STERIS.
On March 26, 2021, STERIS and the Issuer filed with the Commission pursuant to rule 424(b) under the Securities Act of 1933 a prospectus supplement dated March 24, 2021 (the “Prospectus Supplement”) to the prospectus constituting a part of the Registration Statement (the “Prospectus”) relating to the issuance and sale of 2.700% Senior Notes due 2031 and 3.750% Senior Notes due 2051.
Item 1. Description of Registrant’s Securities to be Registered.
The information required by this item is incorporated herein by reference to the information set forth under the caption “Description of notes” in the Prospectus Supplement, and under the captions “Description of Debt Securities” in the Prospectus.
Item 2. Exhibits.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, each of the registrants has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
Dated: April 1, 2021
| STERIS PLC | ||
(Registrant) | ||
| By | /s/ Michael J. Tokich | |
| Name: | Michael J. Tokich | |
| Title: | Senior Vice President and Chief Financial Officer | |
| STERIS IRISH FINCO UNLIMITED COMPANY | ||
(Registrant) | ||
| By | /s/ Michael J. Tokich | |
| Name: | Michael J. Tokich | |
| Title: | Director | |
